Drugs /

ladiratuzumab vedotin

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, anti-LIV-1 antibody-drug conjugate SGN-LIV1A undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in SGN-LIV1A is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.

Clinical Trials

View Clinical Trials for ladiratuzumab vedotin

Ladiratuzumab vedotin has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating ladiratuzumab vedotin, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ladiratuzumab vedotin clinical trials.

Breast carcinoma, adenocarcinoma of the gastroesophageal junction, and cutaneous melanoma are the most common diseases being investigated in ladiratuzumab vedotin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ladiratuzumab Vedotin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ladiratuzumab vedotin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sgn-liv1a, ladiratuzumab vedotin, ladiratuzumab vedotin
Drug Target(s) [2]:
SLC39A6
NCIT ID [1]:
C112001

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.